Literature DB >> 3691610

Acute effects of trimetazidine evaluated by exercise testing.

P Sellier1, P Audouin, B Payen, P Corona, T C Duong, P Ourbak.   

Abstract

A single dose of 60 mg trimetazidine (the normal daily dose) improved exercise capacity in angina pectoris, as reflected by an increase in the duration of exercise, total work performed, and improvement in ECG signs of ischaemia. All these effects occurred without any detectable chronotropic or vasomotor effect. The importance of this study is to demonstrate that these beneficial effects, already well-recognized after chronic administration of 20 mg three times a day, also occur after a single administration equivalent to the normal daily dose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691610     DOI: 10.1007/bf00544569

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  [The effects of trimetazidine on ergometric parameters in exercise-induced angina. Controlled multicenter double blind versus placebo study].

Authors:  P Sellier
Journal:  Arch Mal Coeur Vaiss       Date:  1986-08

2.  [Research on the hemodynamic effects of trimetazidine, in a single administration in man].

Authors:  P Sellier; P Maurice
Journal:  Therapie       Date:  1987 Mar-Apr       Impact factor: 2.070

3.  Vasoactivity of trimetazidine on guinea-pig isolated ductus arteriosus.

Authors:  D Garnier; M J Roulet
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

4.  Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells.

Authors:  I Maridonneau-Parini; C Harpey
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

  4 in total
  11 in total

1.  Combination of trimetazidine with nifedipine in effort angina.

Authors:  C Monpère; M Brochier; J Demange; G Ducloux; J F Warin
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Is the antianginal action of trimetazidine independent of hemodynamic changes?

Authors:  Q Timour; C Harpey; F Durr; G Faucon
Journal:  Cardiovasc Drugs Ther       Date:  1991-12       Impact factor: 3.727

3.  Acute oral trimetazidine administration increases resting technetium 99m sestamibi uptake in hibernating myocardium.

Authors:  M Ciavolella; C Greco; R Tavolaro; G Tanzilli; F Scopinaro; P P Campa
Journal:  J Nucl Cardiol       Date:  1998 Mar-Apr       Impact factor: 5.952

4.  Cardioprotective effect of trimetazidine in severe ischemic cardiomyopathy.

Authors:  H Bricaud; L Brottier; J L Barat; C Combe; B Boussens; J Bonnet
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 5.  Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.

Authors:  K J McClellan; G L Plosker
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 6.  Trimetazidine and Other Metabolic Modifiers.

Authors:  Giacinta Guarini; Alda Huqi; Doralisa Morrone; Paola Francesca Giuseppina Capozza; Mario Marzilli
Journal:  Eur Cardiol       Date:  2018-12

Review 7.  Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis.

Authors:  Clifford D L Folmes; Alexander S Clanachan; Gary D Lopaschuk
Journal:  Curr Atheroscler Rep       Date:  2005-02       Impact factor: 5.113

8.  Combination treatment with trimetazidine and diltiazem in stable angina pectoris.

Authors:  S C Manchanda; S Krishnaswami
Journal:  Heart       Date:  1997-10       Impact factor: 5.994

9.  Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.

Authors:  J M Detry; P Sellier; S Pennaforte; D Cokkinos; H Dargie; P Mathes
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

10.  Trimetazidine for prevention of induced ischemia and reperfusion of guinea pig retina.

Authors:  T Demir; B Turgut; I Ozercan; F C Gul; N Ilhan; U Celiker
Journal:  Clin Ophthalmol       Date:  2010-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.